« Back
Home /
Senicapoc

Senicapoc

Item no.	TMO-T3528-25mg
Manufacturer	TargetMol
CASRN	289656-45-7
Amount	25 mg
Quantity options	100 mg 10 mM x 1 mL (in DMSO) 10 mg 1 mL 200 mg 25 mg 50 mg 5 mg
Category	Reagents & Chemicals Molecules
Type	Molecules
Specific against	other
Citations	1. Ataga KI, et al. Senicapoc (ICA-17043): a potential therapy for the prevention and treatment of hemolysis-associated complications in sickle cell anemia. Expert Opin Investig Drugs. 2009 Feb;18(2):231-9.
Smiles	NC(=O)C(c1ccccc1)(c1ccc(F)cc1)c1ccc(F)cc1
ECLASS 10.1	32169090
ECLASS 11.0	32169090
UNSPSC	12000000
Alias	ICA-17043
Shipping condition	Cool pack
Available
Manufacturer - Targets	Potassium Channel
Shipping Temperature	cool pack
Storage Conditions	-20°
Molecular Weight	323, 34
Target names or alias	ICA-17043
Description	Senicapoc (ICA-17043) is a potent inhibitor of the Gardos channel that ameliorates RBC dehydration in the SAD mouse. It blocks Ca2+-induced rubidium flux from human RBCs with an IC50 value of 11 ± 2 nM (CLT IC50 = 100 ± 12 nM) and inhibits RBC dehydration with an IC50 of 30 ± 20 nM. Senicapoc is used in the treatment of Sickle Cell Disease and Sickle Cell Anemia.
Pathways	Membrane transporter/Ion channel

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

TMO-T3528-25mg-datasheet.pdf

Request safety datasheet

Simple Order Order Subscription

Amount: 25 mg

available

Request delivery time